TY - JOUR
T1 - Variations of dynamic contrast-enhanced magnetic resonance imaging in evaluation of breast cancer therapy response
T2 - A multicenter data analysis challenge
AU - Huang, Wei
AU - Li, Xin
AU - Chen, Yiyi
AU - Li, Xia
AU - Chang, Ming Ching
AU - Oborski, Matthew J.
AU - Malyarenko, Dariya I.
AU - Muzi, Mark
AU - Jajamovich, Guido H.
AU - Fedorov, Andriy
AU - Tudorica, Alina
AU - Gupta, Sandeep N.
AU - Laymon, Charles M.
AU - Marro, Kenneth I.
AU - Dyvorne, Hadrien A.
AU - Miller, James V.
AU - Barbodiak, Daniel P.
AU - Chenevert, Thomas L.
AU - Yankeelov, Thomas E.
AU - Mountz, James M.
AU - Kinahan, Paul E.
AU - Kikinis, Ron
AU - Taouli, Bachir
AU - Fennessy, Fiona
AU - Kalpathy-Cramer, Jayashree
N1 - Funding Information:
The authors thank William Woodward for assistance in breast DCE-MRI data acquisition, Aneela Afzal for preparation of the raw breast DCE-MRI data for sharing by participating QIN centers, and Karen Oh and Nicole Roy for drawing tumor ROIs. The authors acknowledge and appreciate the Radiological Society of North America and NIH/ National Institute of Biomedical Imaging and Bioengineering (NIBIB) Contract No. HHSN268201000050C for supporting development and evaluation of the DCE-MRI DROs.
Funding Information:
Address all correspondence to: Wei Huang, PhD, Advanced Imaging Research Center, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239. E-mail: huangwe@ohsu.edu 1This study was supported by National Institutes of Health (NIH) grants U01-CA154602, U01-CA142565, U01-CA148131, U01-CA166104, U01-CA172320, U01-CA151261, U01-CA140230, U01-CA154601, and U54-EB005149. Received 12 December 2013; Revised 18 March 2014; Accepted 19 March 2014 Copyright © 2014 Neoplasia Press, Inc. All rights reserved 1944-7124/14/$25.00 DOI 10.1593/tlo.13838
PY - 2014/2
Y1 - 2014/2
N2 - Pharmacokinetic analysis of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) time-course data allows estimation of quantitative parameters such as K trans (rate constant for plasma/interstitium contrast agent transfer), ve (extravascular extracellular volume fraction), and vp (plasma volume fraction). A plethora of factors in DCE-MRI data acquisition and analysis can affect accuracy and precision of these parameters and, consequently, the utility of quantitative DCE-MRI for assessing therapy response. In this multicenter data analysis challenge, DCE-MRI data acquired at one center from 10 patients with breast cancer before and after the first cycle of neo- adjuvant chemotherapy were shared and processed with 12 software tools based on the Tofts model (TM), extended TM, and Shutter-Speed model. Inputs of tumor region of interest definition, pre-contrast T1, and arterial input function were controlled to focus on the variations in parameter value and response prediction capability caused by differences in models and associated algorithms. Considerable parameter variations were observed with the within-subject coefficient of variation (wCV) values for K trans and vp being as high as 0.59 and 0.82, respectively. Parameter agreement improved when only algorithms based on the same model were compared, e.g., the K trans intraclass correlation coefficient increased to as high as 0.84. Agreement in parameter percentage change was much better than that in absolute parameter value, e.g., the pairwise concordance correlation coefficient improved from 0.047 (for K trans) to 0.92 (for K trans percentage change) in comparing two TM algorithms. Nearly all algorithms provided good to excellent (univariate logistic regression c-statistic value ranging from 0.8 to 1.0) early prediction of therapy response using the metrics of mean tumor K trans and kep (=K trans/ve, intravasation rate constant) after the first therapy cycle and the corresponding percentage changes. The results suggest that the interalgorithm parameter variations are largely systematic, which are not likely to significantly affect the utility of DCE-MRI for assessment of therapy response.
AB - Pharmacokinetic analysis of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) time-course data allows estimation of quantitative parameters such as K trans (rate constant for plasma/interstitium contrast agent transfer), ve (extravascular extracellular volume fraction), and vp (plasma volume fraction). A plethora of factors in DCE-MRI data acquisition and analysis can affect accuracy and precision of these parameters and, consequently, the utility of quantitative DCE-MRI for assessing therapy response. In this multicenter data analysis challenge, DCE-MRI data acquired at one center from 10 patients with breast cancer before and after the first cycle of neo- adjuvant chemotherapy were shared and processed with 12 software tools based on the Tofts model (TM), extended TM, and Shutter-Speed model. Inputs of tumor region of interest definition, pre-contrast T1, and arterial input function were controlled to focus on the variations in parameter value and response prediction capability caused by differences in models and associated algorithms. Considerable parameter variations were observed with the within-subject coefficient of variation (wCV) values for K trans and vp being as high as 0.59 and 0.82, respectively. Parameter agreement improved when only algorithms based on the same model were compared, e.g., the K trans intraclass correlation coefficient increased to as high as 0.84. Agreement in parameter percentage change was much better than that in absolute parameter value, e.g., the pairwise concordance correlation coefficient improved from 0.047 (for K trans) to 0.92 (for K trans percentage change) in comparing two TM algorithms. Nearly all algorithms provided good to excellent (univariate logistic regression c-statistic value ranging from 0.8 to 1.0) early prediction of therapy response using the metrics of mean tumor K trans and kep (=K trans/ve, intravasation rate constant) after the first therapy cycle and the corresponding percentage changes. The results suggest that the interalgorithm parameter variations are largely systematic, which are not likely to significantly affect the utility of DCE-MRI for assessment of therapy response.
UR - http://www.scopus.com/inward/record.url?scp=84902493742&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902493742&partnerID=8YFLogxK
U2 - 10.1593/tlo.13838
DO - 10.1593/tlo.13838
M3 - Article
AN - SCOPUS:84902493742
SN - 1944-7124
VL - 7
SP - 153
EP - 166
JO - Translational Oncology
JF - Translational Oncology
IS - 1
ER -